Using behavioural insights to reduce unnecessary antibiotic prescriptions by New Zealand doctors
How to cite
Gyani, Alex; Chappell, Nathan; Hayward, Sarah. 2020. "Using behavioural insights to reduce unnecessary antibiotic prescriptions by New Zealand doctors." AEA RCT Registry. AEARCTR-0005526. https://doi.org/10.1257/rct.5526-1.1
Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.
* Primary investigator
Abstract
Antimicrobial resistance (AMR) is a global concern, which the World Health Organisation has named one of the biggest threats to global health, food security and development today. The over-prescription of antibiotics is a key driver of AMR. Unnecessary prescriptions are especially problematic in New Zealand, which had the 7th highest community prescription rate in the OECD in 2015.
The Behavioural Insights Team's previous work in the UK has shown that a letter with personalised feedback to practices can reduce prescriptions of unnecessary antibiotics, and a recent replication in Australia by the Behavioural Economics Team of the Australian Government was even more effective by targeting individual General Practitioners (GPs).
The current trial is being conducted by BIT, and draws on this prior work to tailor it to the New Zealand context. The trial aims to test whether personalised feedback to New Zealand GPs, in the form of a letter, can reduce prescriptions of unnecessary antibiotics. The trial will also test the impact on prescribing to Māori and Pacific patients, who tend to experience worse health outcomes.
Intervention
This trial contains two trial arms: the treatment group (who receive the letter intervention), and the control (who receive no letter intervention).
The trial launched on 19 August 2019, with the one-off letters sent out, and prescribing behaviour will be analysed from September - December 2019.
All high-prescribing GPs in the trial are stratified by area (District Health Board) before randomly allocating each GP to either the treatment group or the control group.
Experimental design
The intervention will be evaluated with a two-armed randomised controlled trial (RCT), with randomisation at the GP level and stratification by District Health Board (area).
Design details
Cited by
No citation data available for this registration yet.